ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
With FDA’s Approval of the Second Biosimilar, Humira to Fight for the Glory of King!
en-cphi.cn
September 01, 2017There comes the second FDA-approved biosimilar of AbbVie’s branded drug Humira (adalimumab), as the tumor necrosis factor (TNF) blocker Cyltezo of Boehringer Ingelheim was approved for marketing by FDA on August 25. -
More Canadians have access to HUMIRA for the treatment of Ulcerative Colitis
firstwordpharma
August 30, 2017HUMIRA? (adalimumab) now reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon, it's also covered by the federal Non-Insured Health Benefits (NIHB) program.
Pharma Sources Insight January 2025
